<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04187573</url>
  </required_header>
  <id_info>
    <org_study_id>DNQS428-01</org_study_id>
    <nct_id>NCT04187573</nct_id>
  </id_info>
  <brief_title>Coil Assisted Flow Diversion Safety and Performance Study</brief_title>
  <acronym>CAFI</acronym>
  <official_title>Coil Assisted Flow Diversion: A Prospective, Single Arm, Multi-center Study to Assess the Safety and Performance of Neqstent in Adjunctive Therapy (CAFI Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cerus Endovascular, Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cerus Endovascular, Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cerus Endovascular is sponsoring a prospective, single arm, multi-center study to document&#xD;
      the safety and performance of Neqstent in adjunctive therapy.&#xD;
&#xD;
      The purpose of the study is to document safety and performance of the Neqstent in adjunctive&#xD;
      therapy in treatment for patients with intracranial aneurysms (IA).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neqstent is designed as an adjunctive therapy for patients with unruptured and failed&#xD;
      bifurcation aneurysm embolizations. Neqstent can be positioned at the neck of the aneurysm&#xD;
      with or without existing coils and other embolization products. Embolization coils should be&#xD;
      added to fill the dome of the aneurysm after placement of Neqstent.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 21, 2020</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, single arm, multi-center study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of subjects with death of any non-accidental cause or any major disabling stroke after treatment or major disabling stroke or death due to neurological cause.</measure>
    <time_frame>From day 31 to 6 months after treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The occlusion rate as adjudicated by a core laboratory.</measure>
    <time_frame>6 months</time_frame>
    <description>Success will be defined as complete occlusion demonstrated by a Grade 1 using the Raymond Roy Scale.</description>
  </primary_outcome>
  <enrollment type="Anticipated">51</enrollment>
  <condition>Intracranial Aneurysm</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Neqstent</intervention_name>
    <description>Adjunctive device providing stable aneurysm neck coverage for the placement of embolization coils within the aneurysm sac and long term stable occlusion of the aneurysm.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient's indication for treatment of unruptured IAs according to the&#xD;
             national/international guidelines.&#xD;
&#xD;
          2. Age 18-80 years at screening&#xD;
&#xD;
          3. Patients who are suitable for non-emergency endovascular embolization of saccular IAs&#xD;
&#xD;
          4. IA located at a bifurcation in the anterior or posterior circulation with dimensions&#xD;
             consistent with implant size selection guidelines included in the IFU&#xD;
&#xD;
          5. Patient has the necessary mental capacity to participate and is willing and able to&#xD;
             participate in the study for the duration of the study follow-up and is able to comply&#xD;
             with study requirements&#xD;
&#xD;
          6. Patient able to able to give their informed consent can be included in this study.&#xD;
             This must be demonstrated by means of a personally signed and dated informed consent&#xD;
             document indicating that the subject has been informed of and understood all pertinent&#xD;
             aspects of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Ruptured aneurysm&#xD;
&#xD;
          2. Patient anatomy or physiology considered unsuitable for endovascular treatment&#xD;
&#xD;
          3. Any patient anatomy, physiology, existing implants with failed aneurysm embolization&#xD;
             that would interfere with the ability for Neqstent to seal at the neck of the&#xD;
             aneurysm. (i.e., compacted coils in close proximity to the neck that prevent good&#xD;
             apposition of the Neqstent to the wall of the aneurysm, stent and/or stent-like&#xD;
             devices whose struts span the aneurysm neck to retain the coil mass that inhibit&#xD;
             access and/or successful Neqstent seating at the aneurysm neck, and/or any aneurysm&#xD;
             that has a failed device and confirmed thrombus-burden inside the aneurysm sac)&#xD;
&#xD;
          4. Contraindication for arterial access&#xD;
&#xD;
          5. Largest measured IA neck diameter &gt;8 mm or &lt;3 mm&#xD;
&#xD;
          6. Target IA contains other devices/implants (e.g., coils) that will prevent complete&#xD;
             expansion of Neqstent&#xD;
&#xD;
          7. Known allergy to platinum, nickel or titanium&#xD;
&#xD;
          8. Known allergy to contrast agents&#xD;
&#xD;
          9. Contraindication to anticoagulants or platelet inhibitor medication&#xD;
&#xD;
         10. Stenosis of the target IA's parent vessel &gt;50%&#xD;
&#xD;
         11. Anticoagulation medications such as warfarin that cannot be discontinued.&#xD;
&#xD;
         12. Pregnant, breastfeeding or women of childbearing potential not on adequate birth&#xD;
             control (only women with a highly effective method of contraception [oral&#xD;
             contraception or intra-uterine device] or sterile women can be enrolled to the study)&#xD;
&#xD;
         13. Acute / chronic renal failure (including dialysis); Creatinine &gt; 2.00 mg/dl or &gt; 182&#xD;
             μmol/L&#xD;
&#xD;
         14. Myocardial Infarction, Stroke or TIA within the last 6 months&#xD;
&#xD;
         15. Any other medical issue within the brain that precludes the device implantation such&#xD;
             as brain surgery, radiation in the target area of intervention, acute traumatic&#xD;
             craniocerebral injury, etc.&#xD;
&#xD;
         16. Other medical conditions that cause an inability to comply with study requirements&#xD;
             and/or that could increase the risk of neurovascular procedures or death within 2&#xD;
             years (e.g., liver failure, cancer, heart failure, chronic obstructive pulmonary&#xD;
             disease, immunosuppression, neural disease, and hematologic disorders etc.)&#xD;
&#xD;
         17. Participating in another study with investigational devices or drugs that would&#xD;
             confound the effects of the study outcomes&#xD;
&#xD;
         18. The presence of condition that may create unacceptable risk during the aneurysm&#xD;
             embolization procedure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Liebig, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum der Universität München</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lori Adels, PhD</last_name>
    <phone>+1 (510) 651 4000</phone>
    <email>lori.adels@cerusendo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Christian Doppler Klinikum</name>
      <address>
        <city>Salzburg</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Killer, MD</last_name>
      <email>m.killer@salk.at</email>
    </contact>
    <investigator>
      <last_name>Monika Killer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alberta Health Sciences</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cian O'Kelly, MD</last_name>
      <email>cian.okelly@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Cian O'Kelly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gyula Gal, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gyula Gal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UK Hamburg</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maxim Bester, MD</last_name>
      <email>mbester@uke.de</email>
    </contact>
    <investigator>
      <last_name>Maxim Bester, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UKSH Kiel</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olav Jansen, MD</last_name>
      <email>olav.jansen@uksh.de</email>
    </contact>
    <investigator>
      <last_name>Olav Jansen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fritz Wodarg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München</name>
      <address>
        <city>Munich</city>
        <zip>D-81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Liebig, MD</last_name>
      <email>Thomas.Liebig@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Thomas Liebig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inerespital Basel</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marios Psychogios, MD</last_name>
      <email>marios.psychgios@usb.ch</email>
    </contact>
    <investigator>
      <last_name>Marios Psychogios, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://cerusendo.com</url>
    <description>Sponsor Web-site</description>
  </link>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>November 27, 2019</study_first_submitted>
  <study_first_submitted_qc>December 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2019</study_first_posted>
  <last_update_submitted>October 1, 2020</last_update_submitted>
  <last_update_submitted_qc>October 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Aneurysm</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

